Latest VR Adviser, LLC Stock Portfolio
VR Adviser, LLC Performance:
2025 Q3: 31.19%YTD: 12.11%2024: 2.55%
Performance for 2025 Q3 is 31.19%, and YTD is 12.11%, and 2024 is 2.55%.
About VR Adviser, LLC and 13F Hedge Fund Stock Holdings
VR ADVISER, LLC is a hedge fund based in NEW YORK, NY. On 30-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $2.4 Billions. In it's latest 13F Holdings report, VR ADVISER, LLC reported an equity portfolio of $1.8 Billions as of 30 Sep, 2025.
The top stock holdings of VR ADVISER, LLC are , , OCUL. The fund has invested 19% of it's portfolio in APOGEE THERAPEUTICS INC and 11.1% of portfolio in METSERA INC.
They significantly reduced their stock positions in PHARVARIS N V (PHVS), ABIVAX SA and COGENT BIOSCIENCES INC (COGT). VR ADVISER, LLC opened new stock positions in MAZE THERAPEUTICS INC and VOR BIOPHARMA INC (VOR). The fund showed a lot of confidence in some stocks as they added substantially to TENAX THERAPEUTICS INC (TENX), CIDARA THERAPEUTICS INC (CDTX) and SAVARA INC (SVRA).
The top stock holdings of VR ADVISER, LLC are , , OCUL. The fund has invested 19% of it's portfolio in APOGEE THERAPEUTICS INC and 11.1% of portfolio in METSERA INC.
They significantly reduced their stock positions in PHARVARIS N V (PHVS), ABIVAX SA and COGENT BIOSCIENCES INC (COGT). VR ADVISER, LLC opened new stock positions in MAZE THERAPEUTICS INC and VOR BIOPHARMA INC (VOR). The fund showed a lot of confidence in some stocks as they added substantially to TENAX THERAPEUTICS INC (TENX), CIDARA THERAPEUTICS INC (CDTX) and SAVARA INC (SVRA).
VR Adviser, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that VR ADVISER, LLC made a return of 31.19% in the last quarter. In trailing 12 months, it's portfolio return was -10.84%.
New Buys
| Ticker | $ Bought |
|---|---|
| maze therapeutics inc | 31,913,800 |
| vor biopharma inc | 24,358,300 |
New stocks bought by VR Adviser, LLC
Additions
| Ticker | % Inc. |
|---|---|
| tenax therapeutics inc | 344 |
| cidara therapeutics inc | 48.15 |
| savara inc | 42.74 |
| septerna inc | 13.02 |
| cytomx therapeutics inc | 11.39 |
| ocular therapeutix inc | 3.13 |
Additions to existing portfolio by VR Adviser, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| pharvaris n v | -67.05 |
| abivax sa | -57.15 |
| upstream bio inc | -49.06 |
| enliven therapeutics inc | -19.87 |
| cogent biosciences inc | -15.89 |
| dianthus therapeutics inc | -3.92 |
VR Adviser, LLC reduced stake in above stock
Sold off
Sector Distribution
VR ADVISER, LLC has about 52.6% of it's holdings in Others sector.
| Sector | % |
|---|---|
| Others | 52.6 |
| Healthcare | 47.4 |
Market Cap. Distribution
VR ADVISER, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 52.6 |
| SMALL-CAP | 34.4 |
| MICRO-CAP | 9.3 |
| NANO-CAP | 2.2 |
| MID-CAP | 1.5 |
Stocks belong to which Index?
About 36.4% of the stocks held by VR ADVISER, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 63.6 |
| RUSSELL 2000 | 36.4 |
VR Adviser, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of VR Adviser, LLC
VR ADVISER, LLC has 33 stocks in it's portfolio. About 69% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. was the most profitable stock for VR ADVISER, LLC last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AGLE | spyre therapeutics inc | 2.53 | 2,685,450 | 45,008,100 | unchanged | 0.00 | ||
| ATXS | astria therapeutics inc | 1.01 | 2,457,350 | 17,889,500 | unchanged | 0.00 | ||
| AVTE | jade biosciences inc | 1.56 | 3,220,360 | 27,791,700 | unchanged | 0.00 | ||
| CDTX | cidara therapeutics inc | 5.10 | 946,788 | 90,664,400 | added | 48.15 | ||
| CGEM | cullinan therapeutics inc | 0.46 | 1,379,960 | 8,183,190 | unchanged | 0.00 | ||
| COGT | cogent biosciences inc | 3.23 | 4,000,000 | 57,440,000 | reduced | -15.89 | ||
| CTMX | cytomx therapeutics inc | 2.79 | 15,561,500 | 49,641,200 | added | 11.39 | ||
| DYN | dyne therapeutics inc | 1.55 | 2,173,910 | 27,500,000 | unchanged | 0.00 | ||
| ERAS | erasca inc | 2.19 | 17,857,100 | 38,928,400 | unchanged | 0.00 | ||
| KALV | kalvista pharmaceuticals inc | 4.61 | 6,728,980 | 81,959,000 | unchanged | 0.00 | ||
| OCUL | ocular therapeutix inc | 8.66 | 13,161,500 | 153,857,000 | added | 3.13 | ||
| ORIC | oric pharmaceuticals inc | 4.46 | 6,596,880 | 79,162,600 | unchanged | 0.00 | ||
| PHVS | pharvaris n v | 0.95 | 674,599 | 16,831,200 | reduced | -67.05 | ||
| SRZN | surrozen inc | 0.46 | 632,931 | 8,155,320 | unchanged | 0.00 | ||
| SVRA | savara inc | 2.55 | 12,681,000 | 45,271,300 | added | 42.74 | ||
| TENX | tenax therapeutics inc | 0.19 | 437,708 | 3,330,960 | added | 344 | ||
| VOR | vor biopharma inc | 1.37 | 499,966 | 24,358,300 | new | |||
| VRDN | viridian therapeutics inc | 4.72 | 3,882,710 | 83,788,900 | unchanged | 0.00 | ||
| apogee therapeutics inc | 18.99 | 8,493,320 | 337,440,000 | unchanged | 0.00 | |||
| metsera inc | 11.05 | 3,750,660 | 196,272,000 | unchanged | 0.00 | |||